Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Item No. 26120

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Dimethyldioctadecylammonium (DDA) is a cationic amphipathic lipid.1,2 DDA liposomes containing an Ag85B-ESAT-6 antigen induce antigen deposition at an intramuscular or subcutaneous injection site in mice, increasing immune cell exposure to the antigen.3 In a guinea pig model of M. tuberculosis infection, spleen bacterial load is reduced and lung and spleen lesion numbers are decreased when the mycobacterial lipid antigens Ac2SGL and PIM2 are administered in liposomes comprised of DDA and a synthetic analog of the mycobacterial cord factor trehalose 6,6-dibehenate (TDB).2 DDA has also been used in the study of lipid bilayer dynamics.4
WARNING This product is not for human or veterinary use.
1. Liposomal vaccine formulations as prophylactic agents: Design considerations for modern vaccines. J. Nanobiotechnology 15(1), 83 (2017).
2. Protective efficacy of a lipid antigen vaccine in a guinea pig model of tuberculosis. Vaccine 35(10), 1395-1402 (2017).
3. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. J. Control Release 142(2), 180-186 (2010).
4. Effects of NSAIDs on the dynamics and phase behavior of DODAB bilayers. J. Phys. Chem. B. 122(43), 9962-9972 (2018).